Comparative Pharmacology
Head-to-head clinical analysis: REDEMPLO versus SPRX 105.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REDEMPLO versus SPRX 105.
REDEMPLO vs SPRX-105
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
REDEMPLO is a synthetic tricyclic analog that acts as a selective serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It binds to the presynaptic transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT), inhibiting their reuptake and increasing synaptic concentrations of these monoamines. Additionally, it has weak antagonistic properties at the 5-HT2A and alpha-2 adrenergic receptors, contributing to its antidepressant and anxiolytic effects.
SPRX-105 is a dual dopamine D2 and serotonin 5-HT1A receptor partial agonist, functioning as a postsynaptic antagonist and presynaptic agonist at D2 receptors, and as a partial agonist at 5-HT1A receptors, modulating neurotransmitter release.
100 mg orally once daily, with or without food.
SPRX-105 is administered orally at a dose of 50 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and end-stage renal disease (up to 40 hours).
12-15 hours in healthy adults; extended to 24-30 hours in renal impairment.
Primarily hepatic metabolism with 70% renal excretion of metabolites and 30% fecal elimination; less than 5% excreted unchanged in urine.
Primarily renal (70-80% unchanged) with 15-20% biliary/fecal elimination.
Category C
Category C
Unknown
Unknown